Dr. Sondak on Ipilimumab in Melanoma

Vernon K. Sondak, MD
Published: Thursday, Nov 07, 2013

Vernon K. Sondak, MD, chair of the Department of Cutaneous Oncology at Moffitt Cancer Center, discusses the use of ipilimumab in the adjuvant setting for patients with melanoma.

Currently, there are a number of studies that are looking at ipilimumab in the adjuvant setting in stage III melanoma. Sondak says that the results of some of these studies are not yet available, but there have been a fair amount of toxicity when ipilimumab is given at the higher dose (10 mg/kg).

Sondak believes that ipilimumab should not be used in the adjuvant setting outside of a clinical study.

Vernon K. Sondak, MD, chair of the Department of Cutaneous Oncology at Moffitt Cancer Center, discusses the use of ipilimumab in the adjuvant setting for patients with melanoma.

Currently, there are a number of studies that are looking at ipilimumab in the adjuvant setting in stage III melanoma. Sondak says that the results of some of these studies are not yet available, but there have been a fair amount of toxicity when ipilimumab is given at the higher dose (10 mg/kg).

Sondak believes that ipilimumab should not be used in the adjuvant setting outside of a clinical study.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Evolving Roles for Targeted Melanoma Therapies: Assessing Rapid Progress in the Field and Looking Toward Future CombinationsFeb 28, 20191.5
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Publication Bottom Border
Border Publication
x